Literature DB >> 31821459

PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.

Shuntaro Ikegawa1, Yusuke Meguri1, Takumi Kondo1, Hiroyuki Sugiura1, Yasuhisa Sando1, Makoto Nakamura1, Miki Iwamoto1, Yoshinobu Maeda1, Ken-Ichi Matsuoka1.   

Abstract

Graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a significant cause of morbidity and mortality. Regulatory T cells (Tregs) are critical mediators of immune tolerance after allo-HSCT. Clinical studies have indicated that programmed cell death 1 (PD-1) blockade before allo-HSCT involves a risk of severe GVHD. However, the mechanisms underlying GVHD induction resulting from PD-1 blockade remain unclear. We investigated the impact of PD-1 expression of donor T cells on T-cell reconstitution and GVHD using murine models. We first demonstrated that inhibition of PD-1 signaling induced aggressive expansion of CD4+ conventional T cells; however, Tregs could not maintain expansion because of high susceptibility to apoptosis, resulting in discordant immune recovery and subsequent development of severe GVHD. We then evaluated the impact of posttransplantation cyclophosphamide (PTCy) on abnormal T-cell reconstitution after PD-1 blockade. PTCy efficiently ameliorated GVHD after transplantation from a PD-1-/- donor and extended overall survival by safely regulating the proliferation and apoptosis of T-cell subsets. Notably, in the first 2 weeks after administration of PTCy, Tregs regained their ability to continuously proliferate, resulting in well-balanced reconstitution of donor T-cell subsets. In conclusion, the influence of PD-1 blockade differed within T-cell subsets and caused unbalanced reconstitution of T-cell subsets, resulting in severe GVHD. PTCy successfully restored T-cell homeostasis and ameliorated GVHD induced by PD-1-/- donor T cells. These findings may help explain the pathophysiology behind the observation that PTCy may mitigate the incidence and impact of GVHD associated with prior exposure to PD-1 blockade.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31821459      PMCID: PMC6963247          DOI: 10.1182/bloodadvances.2019000134

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  60 in total

Review 1.  Regulatory T cells and immune tolerance.

Authors:  Shimon Sakaguchi; Tomoyuki Yamaguchi; Takashi Nomura; Masahiro Ono
Journal:  Cell       Date:  2008-05-30       Impact factor: 41.582

2.  Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Authors:  Alessandra Roberto; Luca Castagna; Veronica Zanon; Stefania Bramanti; Roberto Crocchiolo; James E McLaren; Sara Gandolfi; Paolo Tentorio; Barbara Sarina; Inna Timofeeva; Armando Santoro; Carmelo Carlo-Stella; Benedetto Bruno; Cristiana Carniti; Paolo Corradini; Emma Gostick; Kristin Ladell; David A Price; Mario Roederer; Domenico Mavilio; Enrico Lugli
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

3.  Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Authors:  Christopher G Kanakry; Hua-Ling Tsai; Javier Bolaños-Meade; B Douglas Smith; Ivana Gojo; Jennifer A Kanakry; Yvette L Kasamon; Douglas E Gladstone; William Matsui; Ivan Borrello; Carol Ann Huff; Lode J Swinnen; Jonathan D Powell; Keith W Pratz; Amy E DeZern; Margaret M Showel; Michael A McDevitt; Robert A Brodsky; Mark J Levis; Richard F Ambinder; Ephraim J Fuchs; Gary L Rosner; Richard J Jones; Leo Luznik
Journal:  Blood       Date:  2014-10-14       Impact factor: 22.113

4.  Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells.

Authors:  Masahiro Hirakawa; Tiago R Matos; Hongye Liu; John Koreth; Haesook T Kim; Nicole E Paul; Kazuyuki Murase; Jennifer Whangbo; Ana C Alho; Sarah Nikiforow; Corey Cutler; Vincent T Ho; Philippe Armand; Edwin P Alyea; Joseph H Antin; Bruce R Blazar; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  JCI Insight       Date:  2016-11-03

Review 5.  Homeostatic control of regulatory T cell diversity.

Authors:  Adrian Liston; Daniel H D Gray
Journal:  Nat Rev Immunol       Date:  2014-01-31       Impact factor: 53.106

6.  Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.

Authors:  Abigail E Overacre-Delgoffe; Maria Chikina; Rebekah E Dadey; Hiroshi Yano; Erin A Brunazzi; Gulidanna Shayan; William Horne; Jessica M Moskovitz; Jay K Kolls; Cindy Sander; Yongli Shuai; Daniel P Normolle; John M Kirkwood; Robert L Ferris; Greg M Delgoffe; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Cell       Date:  2017-05-25       Impact factor: 41.582

Review 7.  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Authors:  Charles Herbaux; Reid Merryman; Steven Devine; Philippe Armand; Roch Houot; Franck Morschhauser; Bradley Haverkos
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

8.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

9.  Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.

Authors:  Takahisa Miyao; Stefan Floess; Ruka Setoguchi; Hervé Luche; Hans Joerg Fehling; Herman Waldmann; Jochen Huehn; Shohei Hori
Journal:  Immunity       Date:  2012-02-09       Impact factor: 31.745

Review 10.  Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus.

Authors:  Mohammed S Chaudhry; Enrico Velardi; Florent Malard; Marcel R M van den Brink
Journal:  J Immunol       Date:  2017-01-01       Impact factor: 5.422

View more
  9 in total

1.  Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.

Authors:  Suman Paul; Marianna Zahurak; Leo Luznik; Richard F Ambinder; Ephraim J Fuchs; Javier Bolaños-Meade; Nina Wagner-Johnston; Lode J Swinnen; Laura Schoch; Ravi Varadhan; Richard J Jones; Douglas E Gladstone
Journal:  Biol Blood Marrow Transplant       Date:  2020-06-24       Impact factor: 5.742

2.  Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.

Authors:  Benedetta Rambaldi; Haesook T Kim; Carol Reynolds; Sharmila Chamling Rai; Yohei Arihara; Tomohiro Kubo; Leutz Buon; Mahasweta Gooptu; John Koreth; Corey Cutler; Sarah Nikiforow; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Rizwan Romee
Journal:  Blood Adv       Date:  2021-01-26

3.  Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.

Authors:  Chenchen Zhao; Matthew Bartock; Bei Jia; Neal Shah; David F Claxton; Baldeep Wirk; Kevin L Rakszawski; Myles S Nickolich; Seema G Naik; Witold B Rybka; W Christopher C Ehmann; Raymond J Hohl; Jessica Valentin; Michelle Bernas-Peterson; Emily M Gerber; Michele Zimmerman; Joseph A Mierski; Shin Mineishi; Hong Zheng
Journal:  J Hematol Oncol       Date:  2022-05-19       Impact factor: 23.168

4.  Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma.

Authors:  Chiara De Philippis; Faezeh Legrand-Izadifar; Stefania Bramanti; Laura Giordano; Catalina Montes de Oca; Rémy Duléry; Reda Bouabdallah; Angela Granata; Raynier Devillier; Jacopo Mariotti; Barbara Sarina; Samia Harbi; Valerio Maisano; Sabine Furst; Thomas Pagliardini; Pierre-Jean Weiller; Claude Lemarie; Boris Calmels; Christian Chabannon; Armando Santoro; Mohamad Mohty; Didier Blaise; Luca Castagna
Journal:  Blood Adv       Date:  2020-04-14

5.  Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.

Authors:  Sam R Adhikary; Peter Cuthbertson; Leigh Nicholson; Katrina M Bird; Chloe Sligar; Min Hu; Philip J O'Connell; Ronald Sluyter; Stephen I Alexander; Debbie Watson
Journal:  Immunology       Date:  2021-06-13       Impact factor: 7.215

Review 6.  Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.

Authors:  Sabela Bobillo; Juan Camilo Nieto; Pere Barba
Journal:  Bone Marrow Transplant       Date:  2021-03-19       Impact factor: 5.174

Review 7.  A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform.

Authors:  Hisanori Mayumi
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

8.  Dracocephalum heterophyllum (DH) Exhibits Potent Anti-Proliferative Effects on Autoreactive CD4+ T Cells and Ameliorates the Development of Experimental Autoimmune Uveitis.

Authors:  Jiang Bian; Ke Wang; Qilan Wang; Pu Wang; Ting Wang; Weiyun Shi; Qingguo Ruan
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

Review 9.  Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.

Authors:  Shuntaro Ikegawa; Ken-Ichi Matsuoka
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.